Sarcopenia indicate poor survival in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies.
Body composition
Cancer
Computed tomography
HCC; TACE
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
28
10
2022
accepted:
03
12
2022
medline:
24
7
2023
pubmed:
24
1
2023
entrez:
23
1
2023
Statut:
ppublish
Résumé
Patient selection for transarterial chemoembolization (TACE) has remained challenging. Currently used markers mainly reflect liver function and turned out as less reliable in larger clinical trials. The patients´ body composition has been linked with patient outcome in different cancers. Now, we analyzed the function of different parameters of the patient's body composition as prognostic and/ or predictive parameters in patients that received TACE. CT scans were used to assess five parameters of the individual body composition (skeletal muscle index (SMI), median muscular attenuation (MMA), bone mineral density (BMD) as well as the visceral and subcutaneous fat area) in 89 patients undergoing TACE. Results were correlated with tumor response to TACE and outcome of patients. SMI and visceral fat area were significantly higher in male patients and among patients undergoing TACE for HCC compared to patients with liver metastases. While all parameters of the body composition did not predict response to TACE, patients with an SMI below the ideal cutoff value of 37.76 cm The pre-interventional SMI represents an independent prognostic factor for overall survival following TACE. Assessment of the individual body composition using routine CT scan might help to identify the ideal patients for TACE.
Sections du résumé
BACKGROUND
BACKGROUND
Patient selection for transarterial chemoembolization (TACE) has remained challenging. Currently used markers mainly reflect liver function and turned out as less reliable in larger clinical trials. The patients´ body composition has been linked with patient outcome in different cancers. Now, we analyzed the function of different parameters of the patient's body composition as prognostic and/ or predictive parameters in patients that received TACE.
METHODS
METHODS
CT scans were used to assess five parameters of the individual body composition (skeletal muscle index (SMI), median muscular attenuation (MMA), bone mineral density (BMD) as well as the visceral and subcutaneous fat area) in 89 patients undergoing TACE. Results were correlated with tumor response to TACE and outcome of patients.
RESULTS
RESULTS
SMI and visceral fat area were significantly higher in male patients and among patients undergoing TACE for HCC compared to patients with liver metastases. While all parameters of the body composition did not predict response to TACE, patients with an SMI below the ideal cutoff value of 37.76 cm
CONCLUSION
CONCLUSIONS
The pre-interventional SMI represents an independent prognostic factor for overall survival following TACE. Assessment of the individual body composition using routine CT scan might help to identify the ideal patients for TACE.
Identifiants
pubmed: 36689060
doi: 10.1007/s00432-022-04519-8
pii: 10.1007/s00432-022-04519-8
pmc: PMC10356883
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6181-6190Informations de copyright
© 2023. The Author(s).
Références
Int J Colorectal Dis. 2018 Oct;33(10):1419-1427
pubmed: 29987364
Langenbecks Arch Surg. 2015 Aug;400(6):641-59
pubmed: 26088872
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
J Hepatocell Carcinoma. 2017 Jul 27;4:105-110
pubmed: 28795053
J Hepatol. 2015 Apr;62(1 Suppl):S144-56
pubmed: 25920083
Oncology. 2014;87 Suppl 1:22-31
pubmed: 25427730
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Cureus. 2022 Jul 12;14(7):e26798
pubmed: 35971351
Inflamm Res. 2022 Nov;71(10-11):1305-1313
pubmed: 35962796
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
J Hepatol. 2017 Oct;67(4):749-757
pubmed: 28668580
ESMO Open. 2017 Oct 23;2(4):e000238
pubmed: 29104762
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur Radiol. 2020 Apr;30(4):2199-2208
pubmed: 31834509
Crit Care. 2011;15(1):R63
pubmed: 21324198
Ann Oncol. 2013 Oct;24(10):2565-2570
pubmed: 23857958
Hepatobiliary Surg Nutr. 2014 Dec;3(6):415-8
pubmed: 25568865
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):159-168
pubmed: 35018725
Surg Today. 2018 Feb;48(2):151-157
pubmed: 28699003
PLoS One. 2012;7(12):e51862
pubmed: 23251644
J Hepatol. 2015 Apr;62(4):855-62
pubmed: 25463541
Cancer. 2012 Jan 1;118(1):147-56
pubmed: 21713764
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
Cancers (Basel). 2019 Nov 25;11(12):
pubmed: 31769421
PLoS One. 2017 Oct 24;12(10):e0186990
pubmed: 29065187
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597337
Clin Mol Hepatol. 2016 Mar;22(1):7-17
pubmed: 27044761
Hepatology. 2018 Jan;67(1):381-400
pubmed: 28859222
Ann Med. 2022 Dec;54(1):1562-1569
pubmed: 35639492
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):485-500
pubmed: 30993881